The Food and Drug Administration's Office of Prescription Drug Promotion sent Evolus an untitled letter dated September 28, 2026, saying an Instagram reel for Jeuveau was false or misleading and misbranded the drug. The letter appears on FDA's list of 2026 untitled letters with an issue date of September 28.

Jeuveau (prabotulinumtoxinA-xvfs) is Evolus's prescription injectable neurotoxin. The letter is addressed to the company. It makes no finding about any practice. But it is a five-page record of exactly which claims the agency's reviewers objected to in a patient-testimonial video on Instagram, and why.

According to the letter, the post appeared on both the "evolus" and "jeuveaubyevolus" Instagram accounts and was submitted to the agency by Evolus itself, under cover of Form FDA 2253. FDA said its Bad Ad Program also received a complaint about it. The letter went to Melina Dass, vice president of regulatory affairs at the Newport Beach, California, company.

What the reel said

The reel is a patient testimonial. FDA's description has the patient saying she is "excited about getting rid of my lines," followed by before-and-after clips from Day 0 and Day 2 and a voiceover in which she says the line between her eyebrows "is gone." The caption read, in part: "Lines today. Blurred in as little as 2 days."

FDA objected to the effectiveness claims twice over. The agency said they suggest Jeuveau will get rid of frown lines when its approved indication is for "temporary improvement" in the appearance of moderate to severe glabellar lines. It also took issue with the timeline. The two main studies, EV-001 and EV-002, measured the primary endpoint at Day 30, the letter says, while the Day 2 timepoint was an exploratory endpoint with a lower bar for response. Mixing the two, FDA wrote, "conflates the measures of response."

An on-screen line reading "Individual results may vary" did not fix that, in the agency's view.

Then comes risk. The caption also promoted a masterclass with IPSY, which the letter calls a cosmetic delivery service, and said Evolus was "blurring the lines between what's found in your beauty bag and what happens in the treatment room," with syringe and lipstick icons. FDA said that likens an injectable prescription product to an everyday beauty product and minimizes the risks of a drug that carries a boxed warning for distant spread of toxin effect.

Risk information appeared only at the end of the reel, the letter says, after the testimonial closed on a tagline held for about four seconds against a black background. In the caption, a viewer had to scroll past more benefit claims to reach it.

This was not the first time the agency had raised onset claims with the company. The letter cites advisory comments dated November 22, 2019, in which the office recommended revisions to draft Jeuveau promotions "in order to avoid misrepresenting the onset of treatment effect."

"We are concerned that Evolus is not representing the benefits of Jeuveau in a truthful and non-misleading manner, despite concerns previously expressed by OPDP," the letter says.

What FDA asked for

An untitled letter is not a warning letter; FDA publishes the two on separate lists, and this one sits on the 2026 untitled-letters list. The office asked Evolus to respond in writing within 15 working days of receiving it (the document does not give a receipt date), to list every Jeuveau promotional communication containing similar representations, and to explain its plan for discontinuing them. A company that disagrees can submit its reasoning in the same window.

Signing for the office were Eunice Chung-Davies, a regulatory review officer, and James Dvorsky, deputy director of its Division of Advertising and Promotion Review 2.

The American Med Spa Association reported on the letter on October 5, 2026. We found no public response from Evolus in the documents we read. Its written reply goes to the agency, not to the public, and the letter does not say whether the reel is still live.

Sources